Advertisement

Leprosy-Associated Arthritis

  • Sandra Lúcia Euzébio Ribeiro
  • Ricardo Prado Golmia
  • Lucilene Sales de Souza
  • Gabriel Pacífico Seabra Nunes
  • Morton Scheinberg
Chapter

Abstract

The various clinical presentations of leprosy are associated with osteoarticular manifestations, some transient and some permanent associated with irreversible damage. In this chapter, we review the different clinical presentations, new advances in pathogenesis and autoimmune manifestations, and recent therapies for cases that failed with corticosteroids and thalidomide treatment.

Keywords

Arthritis Erythema nodosum leprosum Thalidomide Anti-TNFs 

References

  1. 1.
    Britton WJ, Lockwood DN. Leprosy. Lancet. 2004;363(9416):1209–19.CrossRefGoogle Scholar
  2. 2.
    Rodrigues LC, Lockwood DNJ. Leprosy now: epidemiology, progress, challenges and research gaps. Lancet Infect Dis. 2011;11:464–70.CrossRefGoogle Scholar
  3. 3.
    World Health Organization. Weekly epidemiological record (Internet). Geneva: World Health Organization; 2017.. (cited 2018 jan 17). 22p.Google Scholar
  4. 4.
    Yamamura M, Wang XH, Ohmen JD, Uyemura K, Rea TH, Bloom BR, Modlin RL. Cytokine patterns of immunologically mediated tissue damage. J Immunol. 1992;149(4):1470–5.PubMedGoogle Scholar
  5. 5.
    Negera E, Bobosha K, Walker SL, Endale B, et al. New insight into the pathogenesis of erythema nodosum leprosum: the role of activated memory T-cells. Front Immunol. 2017;8:1149.CrossRefGoogle Scholar
  6. 6.
    Negera E, Walker SL, Bobosha K, Howe R, Aseffa A, Dockrell HM, Lockwood DN. T-cell regulation in erythema nodosum leprosum. PLoS Negl Trop Dis. 2017;11(10):e0006001.  https://doi.org/10.1371/journal.pntd.0006001. eCollection 2017 Oct.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five group system. Int J Lepr Other Mycobact Dis. 1966;34(3):255–73.PubMedGoogle Scholar
  8. 8.
    Ambrosano L, Santos MASD, Machado ECFA, Pegas ES. Epidemiological profile of leprosy reactions in a referral center in Campinas (SP), Brazil, 2010-2015. An Bras Dermatol. 2018;93(3):460–1.  https://doi.org/10.1590/abd1806-4841.20187260.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Suchonwanit P, Triamchaisri S, Wittayakornrerk S, Rattanakaemakorn P. Leprosy reaction in Thai population: a 20-year retrospective study. Dermatol Res Pract. 2015;2015:253154.  https://doi.org/10.1155/2015/253154. Epub 2015 Oct 5.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Cossermelli-Messina W, Festa Neto C, Cossermelli W. Articular inflammatory manifestations in patients with different forms of leprosy. J Rheumatol. 1998;25(1):111–9.PubMedGoogle Scholar
  11. 11.
    Foss NT. Episódios reacionais na hanseníase. Medicina. 2003;36(2/4):453–9.Google Scholar
  12. 12.
    Holla VV, Kenetker MV, Kolhatkar MK, et al. Leprous synovitis. A study of fifty cases. Int J Lepr Other Mycobact Dis. 1983;51(1):29–32.PubMedGoogle Scholar
  13. 13.
    Modi TH, Lele RD. Acute joint manifestations in leprosy. J Assoc Phys India. 1968;7:247–54.Google Scholar
  14. 14.
    Pereira HL, Ribeiro SL, Pennini SN, et al. Leprosy-related joint involvement. Clin Rheumatol. 2009;28:79–84.CrossRefGoogle Scholar
  15. 15.
    Wakhlu A, Sawlani KK, Himanshu D. Rheumatological manifestations of Hansen’s disease. Indian J Rheumatol. 2018;13:14–9.CrossRefGoogle Scholar
  16. 16.
    Guedes Barbosa LS, Gilbrut B, Shoenfeld Y, Scheinberg MA. Autoantiboides in leprosy sera. Clin Rheumatol. 1996;15:26–8.CrossRefGoogle Scholar
  17. 17.
    Edington FL, Bacellar MO, Machado PR, Barbosa L, Reis E, Reis M, Santiago MB. Anti neutrophil cytoplasmic antibodies in leprosy. Clin Rheumatol. 2007;26(2):208–10.CrossRefGoogle Scholar
  18. 18.
    Chao G, Fang L, Lu C. Leprosy with ANA positive mistaken for connective tissue disease. Clin Rheumatol. 2013;32(5):645–8.CrossRefGoogle Scholar
  19. 19.
    Ribeiro SL, Pereira HL, Silva NP, Sato EI, et al. Long-term persistence of anti-β2 glycoprotein I in treated leprosy patients. Lupus. 2014;23(12):1249–51.CrossRefGoogle Scholar
  20. 20.
    Ribeiro SL, Pereira HL, Mangueira CL, Ferreira CE, Rosseto E, Scheinberg M. The development of arthritis and antinuclear antibodies correlate with serum 25-hydroxyvitamin D levels in patients with leprosy. Ann Rheum Dis. 2012;71(12):2062–3.CrossRefGoogle Scholar
  21. 21.
    Ribeiro SL, Pereira HL, Silva NP, Neves RM, Sato EI. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in leprosy patients with articular involvement. Braz J Med Biol Res. 2008;41(11):1005–10.CrossRefGoogle Scholar
  22. 22.
    Guedes-Barbosa LS, Mangueira C, Scheinberg M. Anticitrulline peptide antibodies (CCP3) in leprosy sera: a negative association. Clin Rheumatol. 2008;27(4):515–6.CrossRefGoogle Scholar
  23. 23.
    Gilburd B, Ziporen L, Zharhary D, Blank M, et al. Antimitochondrial (pyruvate dehydrogenase) antibodies in leprosy. J Clin Immunol. 1994;14(1):14–9.CrossRefGoogle Scholar
  24. 24.
    Dionello CF, Rosa Utiyama SR, Radominski SC, Stahlke E, Stinghen ST, de Messias-Reason IJ. Evaluation of rheumatoid factor and anti-citrullinated peptide antibodies in relation to rheumatological manifestations in patients with leprosy from Southern Brazil. Int J Rheum Dis. 2016;19(10):1024–31.CrossRefGoogle Scholar
  25. 25.
    Negera E, Walker SL, Lema T, Aseffa A, Lockwood DN, Dockrell HM. Complement C1q expression in erythema nodosum leprosum. PLoS Negl Trop Dis. 2018;12(3):e0006321.  https://doi.org/10.1371/journal.pntd.0006321. eCollection 2018 Mar.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lugão HB, Frade MA, Marques W Jr, Foss NT, Nogueira-Barbosa MH. Ultrasonography of leprosy neuropathy: a longitudinal prospective study. PLoS Negl Trop Dis. 2016;10(11):e0005111.CrossRefGoogle Scholar
  27. 27.
    Beltrame A, Barabino G, Cicciò C, Badona Monteiro G, Cavalchini A, Carbognin G, Bisoffi Z. Magnetic resonance imaging in pure neural leprosy. Int J Infect Dis. 2017;60:42–3.CrossRefGoogle Scholar
  28. 28.
    Roy SG, Parida GK, Tripathy S, Das CJ, Kumar R, Roy SG, Parida GK, Tripathy S, Das CJ, Kumar R. Active leprosy neuritis detected on FDG PET/CT. Clin Nucl Med. 2018;43(2):132–3.CrossRefGoogle Scholar
  29. 29.
    Faber WR, Jensema AJ, Goldschmidt WF. Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med. 2006;355(7):739.CrossRefGoogle Scholar
  30. 30.
    Ramien ML, Wong A, Keystone JS. Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. Clin Infect Dis. 2011;52(5):e133–5.CrossRefGoogle Scholar
  31. 31.
    Lluch P, Urruticoechea A, Lluch J, Moll MC, Matos M, Benet JM, Ene L, Cañete JD. Development of leprosy in a patient with rheumatoid arthritis during treatment with etanercept: a case report. Semin Arthritis Rheum. 2012;42(2):127–30.CrossRefGoogle Scholar
  32. 32.
    Laurindo IM, Scheinberg M. Why do some biologic agents induce psoriasis or psoriasiform lesions. Nat Clin Pract Rheumatol. 2008;4:168–9.CrossRefGoogle Scholar
  33. 33.
    Zhang DF, Wang D, Li YY, Yao YG. Integrative analyses of leprosy susceptibility genes indicate a common autoimmune profile. J Dermatol Sci. 2016;82(1):18–27.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Sandra Lúcia Euzébio Ribeiro
    • 1
  • Ricardo Prado Golmia
    • 2
  • Lucilene Sales de Souza
    • 3
  • Gabriel Pacífico Seabra Nunes
    • 4
  • Morton Scheinberg
    • 5
    • 6
    • 7
  1. 1.Department of Internal MedicineRheumatology Section, Medical School Universidade Federal do AmazonasManausBrazil
  2. 2.Center Hospital AACD, Rheumatologist Hospital Israelita Albert Einstein, and Advanced Center for Autoimmune Diseases Hospital BPMiranteSao PauloBrazil
  3. 3.Fundação Alfredo da MataManausBrazil
  4. 4.Department of MedicineUniversidade Nilton LinsManausBrazil
  5. 5.Rheumatology Section, Orthopedics DepartmentHospital Israelita Albert EinsteinSao PauloBrazil
  6. 6.Clinical Research Center Hospital AACDSao PauloBrazil
  7. 7.Advanced Center for Autoimmune Diseases Hospital BPMiranteSao PauloBrazil

Personalised recommendations